Back

iRegene secures U.S. and China trial clearances for NouvSight001

Verifying
  • iRegene secured U.S. and China clinical clearances for NouvSight001 in retinitis pigmentosa.
  • NouvSight001 received Phase I/III clearance in China and Phase I/II clearance in the U.S.
  • The FDA granted NouvSight001 orphan drug designation in 2024.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.